市場調査レポート

商品コード

1762539

非ウイルス性トランスフェクション試薬市場：業界動向と世界の予測 - 非ウイルス性トランスフェクション法タイプ別、応用分野別、エンドユーザー別、主要地域別

Non-Viral Transfection Reagents Market : Industry Trends and Global Forecasts - Distribution by Type of Non-Viral Transfection Method, Application Areas, End-User, and Key Geographical Regions

出版日: 2025年07月04日
発行: Roots Analysis
ページ情報: 英文 254 Pages
納期: 即日から翌営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,799 705,884円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 6,999 1,029,482円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 10,599 1,559,006円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 17,999 2,647,472円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.09円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

非ウイルス性トランスフェクション試薬市場：概要

世界の非ウイルス性トランスフェクション試薬の市場規模は今年、6億3,300万米ドルとなりました。同市場は、2035年までの予測期間中に8.0％のCAGRで拡大すると予測されています。

市場セグメンテーションでは、市場規模および機会分析を以下のパラメータで区分しています：

非ウイルス性トランスフェクション法タイプ

化学的方法
物理的方法
その他の方法

応用分野

臨床
研究

エンドユーザー

学術・研究機関
製薬会社
その他

主要地域

北米
欧州
アジア太平洋
その他の地域

非ウイルス性トランスフェクション試薬市場：成長と動向

長年にわたり、多くの核酸ベースの治療法が規制当局の承認を得ており、その治療の可能性と人気の高まりを裏付けています。その結果、これらの治療法を効率的に送達できるベクターに対する需要が高まっています。特に、トランスフェクションは、特定の担体／ベクターを用いて遺伝物質／核酸を人為的に細胞に導入するプロセスのひとつです。しかし、ウイルスベクターを用いた従来のトランスフェクションには、免疫原性や細胞毒性に関する合併症、開発コストの高さなど、いくつかの課題があります。その結果、非ウイルス性トランスフェクション試薬のような代替遺伝子薬物ビークルの需要が高まっています。非ウイルス性トランスフェクション試薬は、ウイルス性ベクターに関連する炎症や非特異的導入などの制限を克服することができます。さらに、これらのベクターは、ウイルスをベースとした同等品よりもはるかにコスト効率がよく、遺伝子治療市場においてより安価な製品の開発に使用できる可能性を示唆しています。

Non-Viral Transfection Reagents Market-IMG1

非ウイルス性トランスフェクション法では、細胞への遺伝子導入には、宿主細胞にDNAを直接導入する方法と、脂質、ポリマー、リポポリマーとの複合体形成によってキャリア遺伝子を導入する方法があります。いずれの場合も、遺伝子配列はプラスミド（ベクター）に挿入され、宿主内で発現されます。免疫原性が低いため、非ウイルス性トランスフェクション・システムは、合併症のリスクなしに遺伝物質の再投与を可能にします。さらに、このような試薬は大量生産が容易なため、ウイルス性ベクターよりも経済的です。

非ウイルス性トランスフェクション試薬市場：主要インサイト

当レポートでは、非ウイルス性トランスフェクション試薬市場の現状を掘り下げ、業界内の潜在的な成長機会を特定しています。主な調査結果は以下の通りです。

現在、185以上の非ウイルス性トランスフェクション試薬が市場で入手可能であり、このうち60%は遺伝物質のトランスフェクションを可能にするために脂質ベースのキャリアを使用しています。
競合優位性を築くため、業界の利害関係者は、進化する業界ベンチマークに適合するよう、それぞれの製品を積極的に強化しています。
DNA、RNA、タンパク質断片を様々な種類の細胞に導入するために、20種類以上のエレクトロポレーションに基づくシステムと、35種類以上のその他の非ウイルス性トランスフェクションシステムが開発されています。
新興国市場は、市場での競争力を維持するために、それぞれのシステムに高度な機能を統合することに注力しています。
非ウイルス性トランスフェクションおよび試薬開発企業の現在の市場情勢は、主要な世界各地域に既存企業と新興企業の両方が存在することを特徴としています。

Non-Viral Transfection Reagents Market-IMG2

ここ数年、非ウイルス性トランスフェクションの方法と技術に関連する科学文献の出版が顕著に増加しています。
過去4年間で、非ウイルス性トランスフェクション法に関連する特許が約870件出願／付与されており、このうち60％以上が非学術的企業によるものです。
大手製薬企業も有利な可能性を見越して、非ウィルス性トランスフェクションに焦点を当てたいくつかの取り組みを行っています。特に、過去2年間にこのような企業が結んだ共同研究は、すべて前臨床業務に焦点を当てたものでした。
先端治療薬の価格を最適化するため、イノベーターは非ウイルス性トランスフェクション試薬やシステムの開発企業と提携を結ぶと予想されます。
コストは非ウイルス性トランスフェクション技術の採用における重要な決定要因です。価格戦略の枠組みは、試薬の競争価格を評価する上で参入企業を支援するものと思われます。
市場は年率8.0％の成長を遂げる見込みです。予測される機会は、トランスフェクション手法、応用分野、エンドユーザー、主要な地域ごとにうまく分散されることが予想されます。

Non-Viral Transfection Reagents Market-IMG3

非ウイルス性トランスフェクション試薬市場：主要セグメント

非ウイルス性トランスフェクション法タイプ別によって、市場は化学的方法、物理的方法、その他の方法に区分されます。現在、世界の非ウイルス性トランスフェクション試薬市場では、物理的方法が最大シェアを占めています。さらに、その他の方法セグメントの非ウイルス性トランスフェクション試薬市場は、予測期間中に最も高い市場成長性を示すと予想されます。

応用分野別では、市場は臨床応用と調査応用に区分されます。現在、研究用途セグメントが世界の非ウイルス性トランスフェクション試薬市場で最大シェアを占めています。さらに、臨床応用分野の市場は予測期間中、より高いCAGRで成長すると予想されています。

市場はエンドユーザー別では、学術・研究機関、製薬会社、その他のエンドユーザーに区分されます。現在、世界の非ウイルス性トランスフェクション試薬市場で最も高い割合を占めているのは学術研究機関です。しかし、製薬企業セグメントは予測期間中により高いCAGRで成長すると予想されています。

主要地域別に見ると、市場は北米、欧州、アジア太平洋、その他に区分されます。現在、北米が世界の非ウイルス性トランスフェクション試薬市場を独占しており、最大の収益シェアを占めています。さらに、アジア太平洋地域の市場は今後、より高いCAGRで成長する可能性が高いです。

非ウイルス性トランスフェクション試薬市場の参入企業例

Altogen Biosystems
Bio-Rad Laboratories
BEX
BTX
Celsion
Genprex
Inovio Pharmaceuticals
MaxCyte
MilliporeSigma
Nepa Gene
OZ Biosciences
Thermo Fisher Scientific

章の概要
範囲と調査手法
非ウイルス性トランスフェクションシステム開発者：北米における潜在的な戦略的パートナー
非ウイルス性トランスフェクションシステム開発者：欧州における潜在的な戦略的パートナー
非ウイルス性トランスフェクションシステム開発者：アジア太平洋およびその他の地域における潜在的な戦略的パートナー

第11章大手製薬会社の取り組み

章の概要
範囲と調査手法
非ウイルス性トランスフェクション試薬およびシステム開発者：大手製薬会社の取り組み

第12章特許分析

章の概要
範囲と調査手法
非ウイルス性トランスフェクション試薬およびシステム：特許分析
非ウイルス性トランスフェクション試薬およびシステム：特許ベンチマーク分析
非ウイルス性トランスフェクション試薬およびシステム：特許評価分析

第13章出版物の分析

第14章ルーツ分析価格戦略的枠組み

第15章市場規模の評価と機会分析

章の概要
予測調査手法と主要な前提条件
非ウイルス性トランスフェクション試薬およびシステム市場（2035年まで）
非ウイルス性トランスフェクション試薬およびシステム市場：非ウイルス性トランスフェクション法タイプ別分析（2035年まで）
非ウイルス性トランスフェクション試薬およびシステム市場：エンドユーザー別分析（2035年まで）
非ウイルス性トランスフェクション試薬およびシステム市場：応用分野別分析（2035年まで）
非ウイルス性トランスフェクション試薬およびシステム市場：主要地域別分析（2035年まで）

第16章エグゼクティブ洞察

第17章結論

第18章付録I：表形式データ

第19章付録II：企業および組織の一覧

図表

List of Tables

Table 3.1. Specifications of Viral Vectors
Table 4.1. Non-Viral Transfection Reagents: Information on Type of Carrier Used, Compatible Cell Type and Volume of Reagent (per unit)
Table 4.2. Non-Viral Transfection Reagents: Information on Type of Molecule Delivered, Serum Compatibility and Transfection Efficiency
Table 4.3. Non-Viral Transfection Reagents: Information on Storage Temperature, Number of Transfections Per Unit Volume of Reagent and Cost of Reagent (USD)
Table 4.4. Non-Viral Transfection Reagent Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 5.1. Electroporation-based Transfection Systems: Information on Compatible Cell Type and Type of Molecule Delivered
Table 5.2. Electroporation-based Transfection Systems: Information Output Voltage, Pulse and Cost of System (USD)
Table 5.3. Electroporation-based Transfection System Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 6.1. Other Non-Viral Transfection Systems: Information on Compatible Cell Type and Type of Molecule Delivered
Table 6.2 Other Non-Viral Transfection System Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 9.1. List of Companies Profiled
Table 9.2. Altogen Biosystems: Company Snapshot
Table 9.3. Altogen Biosystems: Recent Developments and Future Outlook
Table 9.4. Millipore Sigma: Company Snapshot
Table 9.5. Millipore Sigma: Recent Developments and Future Outlook
Table 9.6. OZ Biosciences: Company Snapshot
Table 9.7. OZ Biosciences: Recent Developments and Future Outlook
Table 9.8. Thermo Fisher Scientific: Company Snapshot
Table 9.9. Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 9.10. BEX: Company Snapshot
Table 9.11. BEX: Recent Developments and Future Outlook
Table 9.12. Bio-Rad Laboratories: Company Snapshot
Table 9.13. Bio-Rad Laboratories: Recent Developments and Future Outlook
Table 9.14. BTX: Company Snapshot
Table 9.15. BTX: Recent Developments and Future Outlook
Table 9.16. MaxCyte: Company Snapshot
Table 9.17. MaxCyte: Recent Developments and Future Outlook
Table 9.18. NepaGene: Company Snapshot
Table 9.19. NepaGene: Recent Developments and Future Outlook
Table 9.20. Imunon: Company Snapshot
Table 9.21. Imunon: Recent Developments and Future Outlook
Table 9.22. Genprex: Company Snapshot
Table 9.23. Genprex: Recent Developments and Future Outlook
Table 9.24. Inovio Pharmaceuticals: Company Snapshot
Table 9.25. Inovio Pharmaceuticals: Recent Developments and Future Outlook
Table 10.1. Most Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in North America
Table 10.2. Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in North America
Table 10.3. Less Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in North America
Table 10.4. Least Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in North America
Table 10.5. Most Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in Europe
Table 10.6. Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in Europe
Table 10.7. Less Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in Europe
Table 10.8. Most Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in Asia-Pacific and Rest of the World
Table 10.9. Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in Asia-Pacific and Rest of the World
Table 10.10. Less Likely Partners: Non-Viral Vector-based Therapy Developers Headquartered in Asia-Pacific and Rest of the World
Table 11.1. Big Pharma Initiatives: List of Non-Viral Transfection Focused Initiatives
Table 12.1. Patent Analysis: Top CPC Sections
Table 12.2. Patent Analysis: Top CPC Symbols
Table 12.3. Patent Analysis: Top CPC Codes
Table 12.4. Patent Analysis: Summary of Benchmarking Analysis
Table 12.5. Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 14.1. Product Price Evaluation Matrix: Based on Transfection Efficiency
Table 14.2. Product Price Evaluation Matrix: Based on Compatible Cell Type
Table 14.3. Product Price Evaluation Matrix: Based on Type of Carrier Used
Table 14.4. Product Price Evaluation Matrix: Based on Type of Molecule Delivered
Table 14.5. Product Price Evaluation Matrix: Based on Serum Compatibility
Table 18.1. Non-Viral Transfection Reagents: Distribution by Type of Carrier Used
Table 18.2. Non-Viral Transfection Reagents: Distribution by Compatible Cell Type
Table 18.3. Non-Viral Transfection Reagents: Distribution by Type of Molecule Delivered
Table 18.4. Non-Viral Transfection Reagents: Distribution by Serum Compatibility
Table 18.5. Non-Viral Transfection Reagent Developers: Distribution by Year of Establishment
Table 18.6. Non-Viral Transfection Reagent Developers: Distribution by Company Size
Table 18.7. Non-Viral Transfection Reagent Developers: Distribution by Location of Headquarters (Region-wise)
Table 18.8. Non-Viral Transfection Reagent Developers: Distribution by Location of Headquarters (Country-wise)
Table 18.9. Electroporation-based Transfection Systems: Distribution by Compatible Cell Type
Table 18.10. Electroporation-based Transfection Systems: Distribution by Type of Molecule Delivered
Table 18.11. Electroporation-based Transfection System Developers: Distribution by Year of Establishment
Table 18.12. Electroporation-based Transfection System Developers: Distribution by Company Size
Table 18.13. Electroporation-based Transfection System Developers: Distribution by Location of Headquarters (Region-wise)
Table 18.14. Electroporation-based Transfection System Developers: Distribution by Location of Headquarters (Country-wise)
Table 18.15. Other Non-Viral Transfection Systems: Distribution by Compatible Cell Type
Table 18.16. Other Non-Viral Transfection Systems: Distribution by Type of Molecule Delivered
Table 18.17. Other Non-Viral Transfection Systems: Distribution by Year of Establishment
Table 18.18. Other Non-Viral Transfection System Developers: Distribution by Company Size
Table 18.19. Other Non-Viral Transfection System Developers: Distribution by Location of Headquarters (Region-wise)
Table 18.20. Other Non-Viral Transfection System Developers: Distribution by Location of Headquarters (Country-wise)
Table 18.21 MilliporeSigma: Annual Revenues, Since 2016 (USD Billion)
Table 18.22 Thermo Fisher Scientific: Annual Revenues, Since 2016 (USD Billion)
Table 18.23 Bio-Rad Laboratories: Annual Revenues, Since 2016 (USD Million)
Table 18.24 MaxCyte: Annual Revenues, Since 2016 (USD Million)
Table 18.25 Genprex: Annual Revenues, Since 2016 (USD Million)
Table 18.26 Inovio Pharmaceuticals: Annual Revenues, Since 2016 (USD Million)
Table 18.27 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative
Table 18.28 Big Pharma Initiatives: Distribution by Number of Initiatives
Table 18.29 Big Pharma Initiatives: Distribution by Type of Initiative
Table 18.30 Big Pharma Initiatives: Distribution by Type of Therapy
Table 18.31 Big Pharma Initiatives: Distribution by Target Therapeutic Area
Table 18.32 Patent Analysis: Distribution by Type of Patent
Table 18.33 Patent Analysis: Distribution by Publication Year
Table 18.34 Patent Analysis: Distribution by Application Year
Table 18.35 Patent Analysis: Distribution by Patent Jurisdiction
Table 18.36 Patent Analysis: Distribution by Type of Applicant
Table 18.37 Patent Analysis: Distribution by CPC Sections
Table 18.38 Leading Players (Industry): Distribution by Number of Patents
Table 18.39 Leading Players (Non-Industry): Distribution by Number of Patents
Table 18.40 Patent Benchmarking: Distribution by Patent Characteristics
Table 18.41 Patent Analysis (Leading Industry Players): Benchmarking by CPC Symbols
Table 18.42 Patent Analysis: Distribution by Patent Age
Table 18.43 Non-Viral Transfection Reagents and Systems: Patent Valuation
Table 18.44 Publication Analysis: Cumulative Year-wise Trend
Table 18.45 Publication Analysis: Distribution by Type of Publication
Table 18.46 Publication Analysis: Distribution by Type of Molecule Delivered
Table 18.47 Publication Analysis: Distribution by Target Therapeutic Area
Table 18.48 Leading Publishers: Distribution by Number of Publications
Table 18.49 Prominent Journals: Distribution by Number of Publications
Table 18.50 Prominent Copyright Holders: Distribution by Number of Publications
Table 18.51 Key Funding Institutes: Distribution by Number of Publications
Table 18.52 Overall Non-Viral Transfection Reagents and Systems Market, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.53 Non-Viral Transfection Systems Market, Conservative, Base and Optimistic Scenario: Distribution by Type of Non-Viral Transfection Method, Till 2035 (USD Million)
Table 18.54 Non-Viral Transfection Systems Market, Conservative, Base and Optimistic Scenario: Distribution by End-User, Till 2035 (USD Million)
Table 18.55 Non-Viral Transfection Systems Market, Conservative, Base and Optimistic Scenario: Distribution by Application Area, Till 2035 (USD Million)
Table 18.56 Non-Viral Transfection Systems Market, Conservative, Base and Optimistic Scenario: Distribution by Key Geographical Regions, Till 2035 (USD Million)
Table 18.57 Non-Viral Transfection Systems Market in North America, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.58 Non-Viral Transfection Systems Market in North America for Pharmaceutical Companies, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.59 Non-Viral Transfection Systems Market in North America for Academic and Research Institutions, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.60 Non-Viral Transfection Systems Market in North America for Other End-Users, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.61 Non-Viral Transfection Systems Market in North America for Research Applications, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.62 Non-Viral Transfection Systems Market in North America for Clinical Applications, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.63 Non-Viral Transfection Systems Market in Europe, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.64 Non-Viral Transfection Systems Market in Europe for Pharmaceutical Companies, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.65 Non-Viral Transfection Systems Market in Europe for Academic and Research Institutions, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.66 Non-Viral Transfection Systems Market in Europe for Other End-Users, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.67 Non-Viral Transfection Systems Market in Europe for Research Applications, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.68 Non-Viral Transfection Systems Market in Europe for Clinical Applications, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.69 Non-Viral Transfection Systems Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.70 Non-Viral Transfection Systems Market in Asia-Pacific for Pharmaceutical Companies, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.71 Non-Viral Transfection Systems Market in Asia-Pacific for Academic and Research Institutions, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.72 Non-Viral Transfection Systems Market in Asia-Pacific for Other End-Users, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.73 Non-Viral Transfection Systems Market in Asia-Pacific for Research Applications, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.74 Non-Viral Transfection Systems Market in Asia-Pacific for Clinical Applications, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.75 Non-Viral Transfection Systems Market in Rest of the World, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.76 Non-Viral Transfection Systems Market in Rest of the World for Pharmaceutical Companies, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.77 Non-Viral Transfection Systems Market in Rest of the World for Academic and Research Institutions, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.78 Non-Viral Transfection Systems Market in Rest of the World for Other End-Users, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.79 Non-Viral Transfection Systems Market in Rest of the World for Research Applications, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 18.80 Non-Viral Transfection Systems Market in Rest of the World for Clinical Applications, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)

List of Figures

Figure 2.1 Executive Summary: Current Landscape of Non-Viral Transfection Reagents
Figure 2.2 Executive Summary: Current Landscape of Electroporation-based Non-Viral Transfection Systems
Figure 2.3 Executive Summary: Current Landscape of Other Non-Viral Transfection Systems
Figure 2.4 Executive Summary: Big Pharma Initiatives
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Publication Analysis
Figure 2.7 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Commonly Used Viral Vectors
Figure 3.2 Types of Non-Viral Transfection Methods
Figure 3.3 Electroporation Mechanism
Figure 3.4 Gene Gun Mechanism
Figure 3.5 Sonoporation Mechanism
Figure 3.6 Microinjection Mechanism
Figure 3.7 Magnetofection Mechanism
Figure 3.8 Applications of Transfection
Figure 4.1 Non-Viral Transfection Reagents: Distribution by Type of Carrier Used
Figure 4.2 Non-Viral Transfection Reagents: Distribution by Compatible Cell Type
Figure 4.3 Non-Viral Transfection Reagents: Distribution by Type of Molecule Delivered
Figure 4.4 Non-Viral Transfection Reagents: Distribution by Serum Compatibility
Figure 4.5 Non-Viral Transfection Reagent Developers: Distribution by Year of Establishment
Figure 4.6 Non-Viral Transfection Reagent Developers: Distribution by Company Size
Figure 4.7 Non-Viral Transfection Reagent Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.8 Non-Viral Transfection Reagent Developers: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 Electroporation-based Transfection Systems: Distribution by Compatible Cell Type
Figure 5.2 Electroporation-based Transfection Systems: Distribution by Type of Molecule Delivered
Figure 5.3 Electroporation-based Transfection System Developers: Distribution by Year of Establishment
Figure 5.4 Electroporation-based Transfection System Developers: Distribution by Company Size
Figure 5.5 Electroporation-based Transfection System Developers: Distribution by Location of Headquarters (Region-wise)
Figure 5.6 Electroporation-based Transfection System Developers: Distribution by Location of Headquarters (Country-wise)
Figure 6.1 Other Non-Viral Transfection Systems: Distribution by Compatible Cell Type
Figure 6.2 Other Non-Viral Transfection Systems: Distribution by Type of Molecule Delivered
Figure 6.3 Other Non-Viral Transfection Systems: Distribution by Year of Establishment
Figure 6.4 Other Non-Viral Transfection System Developers: Distribution by Company Size
Figure 6.5 Other Non-Viral Transfection System Developers: Distribution by Location of Headquarters (Region-wise)
Figure 6.6 Other Non-Viral Transfection System Developers: Distribution by Location of Headquarters (Country-wise)
Figure 7.1 Company Competitiveness Analysis: Distribution of Non-Viral Transfection Reagent Developers based in North America
Figure 7.2 Company Competitiveness Analysis: Distribution of Non-Viral Transfection Reagent Developers based in Europe
Figure 7.3 Company Competitiveness Analysis: Distribution of Non-Viral Transfection Reagent Developers based in Asia-Pacific and Rest of the World
Figure 8.1 Electroporation-based Systems: Distribution of Technologies Offered by Players based in North America
Figure 8.2 Electroporation-based Systems: Distribution of Technologies Offered by Players based in Europe
Figure 8.3 Electroporation-based Systems: Distribution of Technologies Offered by Players based in Asia-Pacific and Rest of the World
Figure 8.4 Other Non-Viral Transfection Systems: Distribution of Technologies Offered by Players based in North America
Figure 8.5 Other Non-Viral Transfection Systems: Distribution of Technologies Offered by Players based in Europe
Figure 8.6 Other Non-Viral Transfection Systems: Distribution of Technologies Offered by Players based in Asia-Pacific and Rest of the World
Figure 9.1 MilliporeSigma: Annual Revenues, Since 2016 (USD Billion)
Figure 9.2 Thermo Fisher Scientific: Annual Revenues, Since 2016 (USD Billion)
Figure 9.3 Bio-Rad Laboratories: Annual Revenues, Since 2016 (USD Million)
Figure 9.4 MaxCyte: Annual Revenues, Since 2016 (USD Million)
Figure 9.5 Genprex: Annual Revenues, Since 2016 (USD Million)
Figure 9.6 Inovio Pharmaceuticals: Annual Revenues, Since 2016 (USD Million)
Figure 11.1 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative
Figure 11.2 Big Pharma Initiatives: Distribution by Number of Initiatives
Figure 11.3 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 11.4 Big Pharma Initiatives: Distribution by Type of Therapy
Figure 11.5 Big Pharma Initiatives: Distribution by Target Therapeutic Area
Figure 12.1 Patent Analysis: Distribution by Type of Patent
Figure 12.2 Patent Analysis: Distribution by Publication Year
Figure 12.3 Patent Analysis: Distribution by Application Year
Figure 12.4 Patent Analysis: Distribution by Patent Jurisdiction
Figure 12.5 Patent Analysis: Distribution by Type of Applicant
Figure 12.6 Patent Analysis: Distribution by CPC Sections
Figure 12.7 Word Cloud: Emerging Focus Areas
Figure 12.8 Leading Players (Industry): Distribution by Number of Patents
Figure 12.9 Leading Players (Non-Industry): Distribution by Number of Patents
Figure 12.10 Patent Benchmarking: Distribution by Patent Characteristics
Figure 12.11 Patent Analysis (Leading Industry Players): Benchmarking by CPC Symbols
Figure 12.12 Patent Analysis: Distribution by Patent Age
Figure 12.13 Non-Viral Transfection Reagents and Systems: Patent Valuation
Figure 13.1 Publication Analysis: Cumulative Year-wise Trend
Figure 13.2 Publication Analysis: Distribution by Type of Publication
Figure 13.3 Publication Analysis: Distribution by Type of Molecule Delivered
Figure 13.4 Publication Analysis: Distribution by Target Therapeutic Area
Figure 13.5 Word Cloud: Key Focus Areas
Figure 13.6 Word Cloud: Popular Cells and Cell Lines
Figure 13.7 Leading Publishers: Distribution by Number of Publications
Figure 13.8 Prominent Journals: Distribution by Number of Publications
Figure 13.9 Prominent Copyright Holders: Distribution by Number of Publications
Figure 13.10 Key Funding Institutes: Distribution by Number of Publications
Figure 14.1 Non-Viral Transfection Reagents and Systems: Roots Analysis Pricing Strategy Framework
Figure 14.2 Non-Viral Transfection Reagents and Systems: Roots Analysis Pricing Strategy Graphical Interpretation
Figure 15.1 Overall Non-Viral Transfection Reagents and Systems Market, Till 2035 (USD Million)
Figure 15.2 Non-Viral Transfection Systems Market: Distribution by Type of Non-Viral Transfection Method, Till 2035 (USD Million)
Figure 15.3 Non-Viral Transfection Systems Market: Distribution by End-User, Till 2035 (USD Million)
Figure 15.4 Non-Viral Transfection Systems Market: Distribution by Application Area, Till 2035 (USD Million)
Figure 15.5 Non-Viral Transfection Systems Market: Distribution by Key Geographical Regions, Till 2035 (USD Million)
Figure 15.6 Non-Viral Transfection Systems Market in North America, Till 2035 (USD Million)
Figure 15.7 Non-Viral Transfection Systems Market in North America for Pharmaceutical Companies, Till 2035 (USD Million)
Figure 15.8 Non-Viral Transfection Systems Market in North America for Academic and Research Institutions, Till 2035 (USD Million)
Figure 15.9 Non-Viral Transfection Systems Market in North America for Other End-Users, Till 2035 (USD Million)
Figure 15.10 Non-Viral Transfection Systems Market in North America for Research Applications, Till 2035 (USD Million)
Figure 15.11 Non-Viral Transfection Systems Market in North America for Clinical Applications, Till 2035 (USD Million)
Figure 15.12 Non-Viral Transfection Systems Market in Europe, Till 2035 (USD Million)
Figure 15.13 Non-Viral Transfection Systems Market in Europe for Pharmaceutical Companies, Till 2035 (USD Million)
Figure 15.14 Non-Viral Transfection Systems Market in Europe for Academic and Research Institutions, Till 2035 (USD Million)
Figure 15.15 Non-Viral Transfection Systems Market in Europe for Other End-Users, Till 2035 (USD Million)
Figure 15.16 Non-Viral Transfection Systems Market in Europe for Research Applications, Till 2035 (USD Million)
Figure 15.17 Non-Viral Transfection Systems Market in Europe for Clinical Applications, Till 2035 (USD Million)
Figure 15.18 Non-Viral Transfection Systems Market in Asia-Pacific, Till 2035 (USD Million)
Figure 15.19 Non-Viral Transfection Systems Market in Asia-Pacific for Pharmaceutical Companies, Till 2035 (USD Million)
Figure 15.20 Non-Viral Transfection Systems Market in Asia-Pacific for Academic and Research Institutions, Till 2035 (USD Million)
Figure 15.21 Non-Viral Transfection Systems Market in Asia-Pacific for Other End-Users, Till 2035 (USD Million)
Figure 15.22 Non-Viral Transfection Systems Market in Asia-Pacific for Research Applications, Till 2035 (USD Million)
Figure 15.23 Non-Viral Transfection Systems Market in Asia-Pacific for Clinical Applications, Till 2035 (USD Million)
Figure 15.24 Non-Viral Transfection Systems Market in Rest of the World, Till 2035 (USD Million)
Figure 15.25 Non-Viral Transfection Systems Market in Rest of the World for Pharmaceutical Companies, Till 2035 (USD Million)
Figure 15.26 Non-Viral Transfection Systems Market in Rest of the World for Academic and Research Institutions, Till 2035 (USD Million)
Figure 15.27 Non-Viral Transfection Systems Market in Rest of the World for Other End-Users, Till 2035 (USD Million)
Figure 15.28 Non-Viral Transfection Systems Market in Rest of the World for Research Applications, Till 2035 (USD Million)
Figure 15.29 Non-Viral Transfection Systems Market in Rest of the World for Clinical Applications, Till 2035 (USD Million)
Figure 17.1. Conclusion: Current Landscape of Non-Viral Transfection Reagents
Figure 17.2 Conclusion: Current Landscape of Electroporation-based Non-Viral Transfection Systems
Figure 17.3 Conclusion: Current Landscape of Other Non-Viral Transfection Systems
Figure 17.4 Conclusion: Big Pharma Initiatives
Figure 17.5 Conclusion: Patent Analysis
Figure 17.6 Conclusion: Publication Analysis
Figure 17.7 Conclusion: Market Forecast and Opportunity Analysis

Product Code: RA100420

NON-VIRAL TRANSFECTION REAGENTS MARKET: OVERVIEW

As per Roots Analysis, the global non-viral transfection reagents market valued at USD 633 million in the current year is projected to grow at a CAGR of 8.0% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Non-Viral Transfection Method

Chemical Methods
Physical Methods
Other Methods

Application Areas

Clinical Applications
Research Applications

End-User

Academic and Research Institutions
Pharmaceutical Companies
Other End-Users

Key Geographical Regions

North America
Europe
Asia-Pacific
Rest of the World

NON-VIRAL TRANSFECTION REAGENTS MARKET: GROWTH AND TRENDS

Over the years, a large number of nucleic acid-based therapies have gained regulatory approval, underscoring both their therapeutic potential and rising popularity. As a result, there has been an increased demand for vectors capable of efficiently delivering these therapies. Notably, transfection is one such process of artificially introducing genetic material / nucleic acid into the cells with the use of specific carriers / vectors. However, conventional transfection through viral vectors poses several challenges, such as complications related to immunogenicity and cytotoxicity along with being a cost-intensive development process. Consequently, the demand for alternative gene drug vehicles such as non-viral transfection reagents has increased. The non-viral transfection reagents can overcome limitations, such as inflammation and non-specific transduction, associated with viral vectors. Further, these vectors are significantly cost effective than their virus-based counterparts, implying the potential for use in the development of more affordable products in the gene therapy market.

In non-viral transfection method, the gene transfer to cells may involve either direct introduction of DNA into the host cell, or the delivery of carrier gene by a complex formation with lipids, polymers or lipo-polymers. In both cases, gene sequences are inserted into a plasmid (vector) for its expression within the host. Due to low immunogenicity, non-viral transfection systems allow re-dosing of genetic material without the risk of complications. Moreover, such reagents are more economical than viral vectors as they can be easily produced in large quantities.

NON-VIRAL TRANSFECTION REAGENTS MARKET: KEY INSIGHTS

The report delves into the current state of the non-viral transfection reagents market and identifies potential growth opportunities within industry. Some key findings from the report include:

Over 185 non-viral transfection reagents are currently available in the market; of these, ~60% use lipid-based carriers to enable the transfection of genetic material.
In pursuit of building a competitive edge, industry stakeholders are actively enhancing their respective offerings to comply with the evolving industry benchmarks.
Over 20 electroporation-based systems and more than 35 other non-viral transfection systems have been developed for the delivery of DNA, RNA and protein fragments, in different types of cells.
Developers are focused on the integration of advanced features in their respective systems, in order to maintain their competitive position in the market.
The current market landscape of non-viral transfection and reagent developers features the presence of both established and emerging players, located across key global regions.

A notable increase in published scientific literature related to non-viral transfection methods and techniques has been observed in the past few years.
In the past four years, around 870 patents have been filed / granted related to non-viral transfection methods; of these, over 60% of the patents were by non-academic players.
Foreseeing a lucrative potential, big pharma players have also undertaken several initiatives focused on non-viral transfection; notably, all collaborations inked by such players in the past two years were focused on preclinical operations.
In order to optimize the price of advanced therapies, innovators are anticipated to forge alliances with non-viral transfection reagent and system developers.
Cost is a key determinant for the adoption of non-viral transfection techniques; the pricing strategy framework is likely to assist players in evaluating competitive prices for their reagents.
The market is likely to witness an annual growth of 8.0%; the projected opportunity is expected to be well distributed across different transfection methods, application areas, end-users and key geographical regions

NON-VIRAL TRANSFECTION REAGENTS MARKET: KEY SEGMENTS

Physical Methods Segment holds the Largest Share of the Non-Viral Transfection Reagents Market

Based on the type of non-viral transfection method, the market is segmented into chemical methods, physical methods and other methods. At present, the physical methods segment holds the maximum share of the global non-viral transfection reagents market. Further, the non-viral transfection reagents market for other methods segment is expected to show the highest market growth potential during the forecast period.

By Application Areas, Clinical Applications is the Fastest Growing Segment of the Global Non-Viral Transfection Reagents Market

Based on the application areas, the market is segmented into clinical applications and research applications. At present, the research applications segment holds the maximum share of the global non-viral transfection reagents market. Further, the market for clinical applications segment is expected to grow at a higher CAGR during the forecast period.

By End-User, Academic and Research Institutions Segment Accounts for the Largest Share of the Global Non-Viral Transfection Reagents Market

Based on the end-user, the market is segmented into academic and research institutions, pharmaceutical companies and other end-users. Currently, the academic and research institutions segment captures the highest proportion of the global non-viral transfection reagents market. However, the pharmaceutical companies segment is expected to grow at a higher CAGR during the forecast period.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. Currently, North America dominates the global non-viral transfection reagents market and accounts for the largest revenue share. Further, the market in Asia-Pacific is likely to grow at a higher CAGR in the coming future.

Example Players in the Non-Viral Transfection Reagents Market

Altogen Biosystems
Bio-Rad Laboratories
BEX
BTX
Celsion
Genprex
Inovio Pharmaceuticals
MaxCyte
MilliporeSigma
Nepa Gene
OZ Biosciences
Thermo Fisher Scientific

NON-VIRAL TRANSFECTION REAGENTS MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global non-viral transfection reagents market, focusing on key market segments, including [A] type of non-viral transfection method, [B] application areas, [C] end-user and [D] key geographical regions.
Non-Viral Transfection Reagents Market Landscape: A comprehensive evaluation of the companies developing non-viral transfection reagents, based on several relevant parameters, such as [A] type of carrier used, [B] compatible cell type, [C] type of molecule delivered and [D] serum compatibility. Additionally, a comprehensive evaluation of non-viral transfection reagent developers, based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
Electroporation-Based Transfection Systems Market Landscape: A detailed analysis of the companies developing electroporation-based non-viral transfection systems, based on several relevant parameters, such as [A] compatible cell type and [B] type of molecule delivered. Additionally, a comprehensive evaluation of electroporation transfection systems developers, based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
Other Non-Viral Transfection Systems Market Landscape: An insightful evaluation of the companies developing other non-viral transfection systems, based on several relevant parameters, such as [A] compatible cell type and [B] type of molecule delivered. Additionally, a comprehensive evaluation of other non-viral transfection systems developers, based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
Company Competitiveness Analysis: A comprehensive competitive analysis of non-viral transfection reagent and system developers, examining factors, such as [A] developer strength and [B] product portfolio strength.
Technology Competitiveness Analysis: A detailed analysis of electroporation transfection systems and other non-viral transfection systems, examining factors, such as [A] developer strength and [B] product portfolio strength.
Company Profiles: In-depth profiles of key players that are engaged in the development of non-viral transfection reagents and systems, focusing on [A] overview of the company, [B] financial information (if available) and [C] recent developments and an informed future outlook.
Potential Strategic Partners: An insightful analysis of more than 80 cell and gene therapy developers that are likely to partner with non-viral transfection reagent and system developers, based on several relevant parameters, such as [A] pipeline maturity, [B] developer strength, [C] pipeline strength and [D] type of therapy.
Benchmark Analysis: A comprehensive benchmark analysis of various non-viral focused initiatives undertaken by big pharma players, based on several relevant parameters, such as [A] year of initiative, [B] type of initiative, [C] type of therapy and [D] target therapeutic area.
Patent Analysis: An in-depth analysis of patents filed / granted till date in the non-viral transfection systems domain, based on various relevant parameters, such as [A] type of patent, [B] publication year, [C] application year, [D] geography, [E] type of applicant, [F] CPC symbols, [G] emerging focus areas, [H] leading players (in terms of number of patents granted / filed), [I] patent benchmarking and [J] valuation analysis.
Publication Analysis: An insightful analysis of over 450 peer-reviewed, scientific articles focused on non-viral transfection reagents and systems, based on various relevant parameters, such as [A] year of publication, [B] type of publication, [C] type of molecule delivered, [D] target therapeutic area, [E] key focus areas, [F] popular cells and cell lines. Additionally, the section includes analysis of the leading publishers across different geographies and key journals (in terms of number of articles published).
Roots Analysis Pricing Strategy Framework: A detailed framework for analyzing the pricing strategy of a company's non-viral transfection reagents and its competitive market position, including an equation to estimate reagent prices based on their characteristics.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
- 1.2.1. Research Assumptions
- 1.2.2. Project Methodology
- 1.2.3. Forecast Methodology
- 1.2.4. Robust Quality Control
- 1.2.5. Key Considerations
  - 1.2.5.1. Demographics
  - 1.2.5.2. Economic Factors
  - 1.2.5.3. Government Regulations
  - 1.2.5.4. Supply Chain
  - 1.2.5.5. COVID Impact / Related Factors
  - 1.2.5.6. Market Access
  - 1.2.5.7. Healthcare Policies
  - 1.2.5.8. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Introduction to Transfection
3.3. Methods of Transfection
- 3.3.1. Viral Transfection Systems
  - 3.3.1.1. Types of Viral Transfection Vectors
    - 3.3.1.1.1. Adeno-associated Virus-based Vectors
    - 3.3.1.1.2. Adenovirus-based Vectors
    - 3.3.1.1.3. Herpes Virus-based Vectors
    - 3.3.1.1.4. Lentivirus-based Vectors
    - 3.3.1.1.5. Retroviral-based Vectors
- 3.3.2. Non-Viral Transfection Systems
  - 3.3.2.1. Chemical-based Transfection
    - 3.3.2.1.1. Lipoplexes-based Transfection
    - 3.3.2.1.2. Polyplexes-based Transfection
    - 3.3.2.1.3. Lipo-polyplexes-based Transfection
    - 3.3.2.1.4. Dendrimer-based Transfection
    - 3.3.2.1.5. Cell Penetrating Peptide-based Transfection
  - 3.3.2.2. Physical Transfection Systems
    - 3.3.2.2.1. Electroporation-based Transfection
    - 3.3.2.2.2. Gene Gun-based Transfection
    - 3.3.2.2.3. Sonoporation-based Transfection
    - 3.3.2.2.4. Microinjection-based Transfection
    - 3.3.2.2.5. Magnetofection-based Transfection
3.4. Applications of Transfection
- 3.4.1. Advanced Therapeutic Medicinal Product Development
- 3.4.2. Gene Silencing
- 3.4.3. Generation of Stable Cell Lines
- 3.4.4. Large-scale Protein Production
- 3.4.5. Stem Cell Engineering
3.5. Future Perspectives

4. NON-VIRAL TRANSFECTION REAGENTS: MARKET LANDSCAPE

4.1. Chapter Overview
4.2. List of Non-Viral Transfection Reagents
- 4.2.1. Analysis by Type of Carrier Used
- 4.2.2. Analysis by Compatible Cell Type
- 4.2.3. Analysis by Type of Molecule Delivered
- 4.2.4. Analysis by Serum Compatibility
4.3 List of Non-Viral Transfection Reagent Developers
- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Location of Headquarters (Region-wise)
- 4.3.4. Analysis by Location of Headquarters (Country-wise)

5. ELECTROPORATION-BASED TRANSFECTION SYSTEMS: MARKET LANDSCAPE

5.1. Chapter Overview
5.2. List of Electroporation-based Transfection Systems
- 5.2.1. Analysis by Compatible Cell Type
- 5.2.2. Analysis by Type of Molecule Delivered
5.3. List of Electroporation-based Transfection System Developers
- 5.3.1. Analysis by Year of Establishment
- 5.3.2. Analysis by Company Size
- 5.3.3. Analysis by Location of Headquarters (Region -wise)
- 5.3.4. Analysis by Location of Headquarters (Country-wise)

6. OTHER NON-VIRAL TRANSFECTION SYSTEMS: MARKET LANDSCAPE

6.1. Chapter Overview
6.2. List of Other Non-Viral Transfection Systems
- 6.2.1. Analysis by Compatible Cell Type
- 6.2.2. Analysis by Type of Molecule Delivered
6.3. List of Other Non-Viral Transfection System Developers
- 6.3.1. Analysis by Year of Establishment
- 6.3.2. Analysis by Company Size
- 6.3.3. Analysis by Location of Headquarters (Region-wise)
- 6.3.4. Analysis by Location of Headquarters (Country-wise)

7. COMPANY COMPETITIVENESS ANALYSIS

7.1. Chapter Overview
7.2. Methodology and Key Parameters
7.3. Non-Viral Transfection Reagent Developers: Company Competitiveness Analysis
- 7.3.1. Non-Viral Transfection Reagent Developers based in North America
- 7.3.2. Non-Viral Transfection Reagent Developers based in Europe
- 7.3.3. Non-Viral Transfection Reagent Developers based in Asia-Pacific and Rest of the World

8. TECHNOLOGY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Electroporation-based Transfection Systems: Technology Competitiveness Analysis
- 8.3.1. Technologies Offered by Players based in North America
- 8.3.2. Technologies Offered by Players based in Europe
- 8.3.3. Technologies Offered by Players based in Asia-Pacific and Rest of the World
8.4. Other Non-Viral Transfection Systems: Technology Competitiveness Analysis
- 8.4.1. Technologies Offered by Players based in North America
- 8.4.2. Technologies Offered by Players based in Europe
- 8.4.3. Technologies Offered by Players based in Asia-Pacific and Rest of the World

9. COMPANY PROFILES

9.1. Chapter Overview
9.2. Non-Viral Transfection Reagent Developers
- 9.2.1. MilliporeSigma
  - 9.2.1.1. Company Overview
  - 9.2.1.2. Financial Information
  - 9.2.1.3. Recent Developments and Future Outlook
- 9.2.2. OZ Biosciences
  - 9.2.2.1. Company Overview
  - 9.2.2.2. Recent Developments and Future Outlook
- 9.2.3. Thermo Fisher Scientific
  - 9.2.3.1. Company Overview
  - 9.2.3.2. Financial Information
  - 9.2.3.3. Recent Development and Future Outlook
9.3. Electroporation-based Transfection System Developers
- 9.3.1. BEX
  - 9.3.1.1. Company Overview
  - 9.3.1.2. Recent Developments and Future Outlook
- 9.3.2. Bio-Rad Laboratories
  - 9.3.2.1. Company Overview
  - 9.3.2.2. Financial Information
  - 9.3.2.3. Recent Developments and Future Outlook
- 9.3.3. BTX (A subsidiary of Harvard Bioscience)
  - 9.3.3.1. Company Overview
  - 9.3.3.2. Recent Developments and Future Outlook
- 9.3.4. MaxCyte
  - 9.3.4.1. Company Overview
  - 9.3.4.2. Financial Information
  - 9.3.4.3. Recent Developments and Future Outlook
- 9.3.5. NepaGene
  - 9.3.5.1. Company Overview
  - 9.3.5.2. Recent Developments and Future Outlook
9.4. Other Non-Viral Transfection System Developers
- 9.4.1. Imunon (Formerly known as Celsion)
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Recent Developments and Future Outlook
- 9.4.2. Genprex
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Financial Information
  - 9.4.2.3. Recent Developments and Future Outlook
- 9.4.3. Inovio Pharmaceuticals
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Financial Information
  - 9.4.3.3. Recent Developments and Future Outlook

10. POTENTIAL STRATEGIC PARTNERS

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Non-Viral Transfection System Developers: Potential Strategic Partners in North America
- 10.3.1. Most Likely Partners
- 10.3.2. Likely Partners
- 10.3.3. Less Likely Partners
- 10.3.4. Least Likely Partners
10.4. Non-Viral Transfection System Developers: Potential Strategic Partners in Europe
- 10.4.1. Most Likely Partners
- 10.4.2. Likely Partners
- 10.4.3. Less Likely Partners
10.5. Non-Viral Transfection System Developers: Potential Strategic Partners in Asia-Pacific and Rest of the World
- 10.5.1. Most Likely Partners
- 10.5.2. Likely Partners
- 10.5.3. Less Likely Partners

11. BIG PHARMA INITIATIVES

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. None-Viral Transfection Reagents and System Developers: Big Pharma Initiatives
- 11.3.1. Analysis by Year of Initiative
- 11.3.2. Analysis by Number of Initiative
- 11.3.3. Analysis by Type of Initiative
- 11.3.4. Analysis by Type of Therapy
- 11.3.5. Analysis by Target Therapeutic Area

12. PATENT ANALYSIS

12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Non-Viral Transfection Reagents and Systems: Patent Analysis
- 12.3.1. Analysis by Publication Year
- 12.3.2. Analysis by Application Year
- 12.3.3. Analysis by Patent Jurisdiction
- 12.3.4. Analysis by Type of Applicant
- 12.3.5. Analysis by CPC Sections
- 12.3.6. Analysis by Emerging Focus Areas (Word Cloud Representation)
- 12.3.7. Leading Players: Analysis by Number of Patents
12.4. Non-Viral Transfection Reagents and Systems: Patent Benchmarking Analysis
- 12.4.1. Analysis by Patent Characteristics (CPC Symbols)
- 12.4.2. Analysis by Geography
12.5. Non-Viral Transfection Reagents and Systems: Patent Valuation Analysis

13. PUBLICATION ANALYSIS

13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Non-Viral Transfection Reagents and Systems: Recent Publications
13.4. Analysis by Year of Publication
13.5. Analysis by Type of Publication
13.6. Analysis by Type of Molecule Delivered
13.7. Analysis by Target Therapeutic Area
13.8. Analysis by Key Focus Areas (Word Cloud Representation)
13.9. Analysis by Prominent Cells and Cell Lines (Word Cloud Representation)
13.10. Leading Publishers: Analysis by Number of Publications
13.11. Prominent Journals: Analysis by Number of Publications
13.12. Prominent Copyright Holders: Analysis by Number of Publications
13.13. Key Funding Institutes: Analysis by Number of Publications

14. ROOTS ANALYSIS PRICING STRATEGY FRAMEWORK

14.1. Chapter Overview
14.2. Roots Analysis Framework
- 14.2.1. Methodology
- 14.2.2. Theoretical Framework and Price Evaluation Hypothesis
- 14.2.3. Results and Interpretation
  - 14.2.3.1. Product Price Evaluation Matrix: Based on Transfection Efficiency
  - 14.2.3.2. Product Price Evaluation Matrix: Based on Compatible Cell Type
  - 14.2.3.3. Product Price Evaluation Matrix: Based on Type of Carrier Used
  - 14.2.3.4. Product Price Evaluation Matrix: Based on Type of Molecule Delivered
  - 14.2.3.5. Product Price Evaluation Matrix: Based on Serum Compatibility
14.3. Concluding Remarks

15. MARKET SIZING AND OPPORTUNITY ANALYSIS

15.1. Chapter Overview
15.2. Forecast Methodology and Key Assumptions
15.3. Non-Viral Transfection Reagents and Systems Market, Till 2035
15.4. Non-Viral Transfection Reagents and Systems Market: Analysis by Type of Non-Viral Transfection Method, Till 2035
15.5. Non-Viral Transfection Reagents and Systems Market: Analysis by End-User, Till 2035
15.6. Non-Viral Transfection Reagents and Systems Market: Analysis by Application Area, Till 2035
15.7. Non-Viral Transfection Reagents and Systems Market: Analysis by Key Geographical Regions, Till 2035
- 15.7.1. Non-Viral Transfection Reagents and Systems Market in North America, Till 2035
  - 15.7.1.1. Non-Viral Transfection Reagents and Systems Market in North America: Analysis by Type of End-User, Till 2035
    - 15.7.1.1.1. Non-Viral Transfection Reagents and Systems Market in North America for Pharmaceutical Companies, Till 2035
    - 15.7.1.1.2. Non-Viral Transfection Reagents and Systems Market in North America for Academic and Research Institutions, Till 2035
    - 15.7.1.1.3. Non-Viral Transfection Reagents and Systems Market in North America for Other End-Users, Till 2035
  - 15.7.1.2. Non-Viral Transfection Reagents and Systems Market in North America: Analysis by Application Area, Till 2035
    - 15.7.1.2.1. Non-Viral Transfection Reagents and Systems Market in North America for Research Applications, Till 2035
    - 15.7.1.2.2. Non-Viral Transfection Reagents and Systems Market in North America for Clinical Applications, Till 2035
- 15.7.2. Non-Viral Transfection Reagents and Systems Market in Europe, Till 2035
  - 15.7.2.1. Non-Viral Transfection Reagents and Systems Market in Europe: Analysis by Type of End-User, Till 2035
    - 15.7.2.1.1. Non-Viral Transfection Reagents and Systems Market in Europe for Pharmaceutical Companies, Till 2035
    - 15.7.2.1.2. Non-Viral Transfection Reagents and Systems Market in Europe for Academic and Research Institutions, Till 2035
    - 15.7.2.1.3. Non-Viral Transfection Reagents and Systems Market in Europe for Other End-Users, Till 2035
  - 15.7.2.2. Non-Viral Transfection Reagents and Systems Market in Europe: Analysis by Application Area, Till 2035
    - 15.7.2.2.1. Non-Viral Transfection Reagents and Systems Market in Europe for Research Applications, Till 2035
    - 15.7.2.2.2. Non-Viral Transfection Reagents and Systems Market in Europe for Clinical Applications, Till 2035
- 15.7.3. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific, Till 2035
  - 15.7.3.1. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific: Analysis by Type of End-User, Till 2035
    - 15.7.3.1.1. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific for Pharmaceutical Companies, Till 2035
    - 15.7.3.1.2. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific for Academic and Research Institutions, Till 2035
    - 15.7.3.1.3. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific for Other End-Users, Till 2035
  - 15.7.3.2. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific: Analysis by Application Area, Till 2035
    - 15.7.3.2.1. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific for Research Applications, Till 2035
    - 15.7.3.2.2. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific for Clinical Applications, Till 2035
- 15.7.4. Non-Viral Transfection Reagents and Systems Market in Rest of the World, Till 2035
  - 15.7.4.1. Non-Viral Transfection Reagents and Systems Market in Rest of the World: Analysis by Type of End-User, Till 2035
    - 15.7.4.1.1. Non-Viral Transfection Reagents and Systems Market in Rest of the World for Pharmaceutical Companies, Till 2035
    - 15.7.4.1.2. Non-Viral Transfection Reagents and Systems Market in Rest of the World for Academic and Research Institutions, Till 2035
    - 15.7.4.1.3. Non-Viral Transfection Reagents and Systems Market in Rest of the World for Other End-Users, Till 2035
  - 15.7.4.2. Non-Viral Transfection Reagents and Systems Market in Rest of the World: Analysis by Application Area, Till 2035
    - 15.7.4.2.1. Non-Viral Transfection Reagents and Systems Market in Rest of the World for Research Applications, Till 2035
    - 15.7.4.2.2. Non-Viral Transfection Reagents and Systems Market in Rest of the World for Clinical Applications, Till 2035

非ウイルス性トランスフェクション試薬市場：業界動向と世界の予測 - 非ウイルス性トランスフェクション法タイプ別、応用分野別、エンドユーザー別、主要地域別

Non-Viral Transfection Reagents Market : Industry Trends and Global Forecasts - Distribution by Type of Non-Viral Transfection Method, Application Areas, End-User, and Key Geographical Regions

非ウイルス性トランスフェクション試薬市場：概要

非ウイルス性トランスフェクション試薬市場：成長と動向

非ウイルス性トランスフェクション試薬市場：主要インサイト

非ウイルス性トランスフェクション試薬市場：主要セグメント

非ウイルス性トランスフェクション試薬市場の参入企業例

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 非ウイルス性トランスフェクション試薬：市場情勢

第5章 電気穿孔法別トランスフェクションシステム：市場情勢

第6章 その他の非ウイルス性トランスフェクションシステム：市場情勢

第7章 企業競争力分析

第8章 技術競争力分析

第9章 企業プロファイル

第10章 潜在的な戦略的パートナー

第11章 大手製薬会社の取り組み

第12章 特許分析

第13章 出版物の分析

第14章 ルーツ分析価格戦略的枠組み

第15章 市場規模の評価と機会分析

第16章 エグゼクティブ洞察

第17章 結論

第18章 付録I：表形式データ

第19章 付録II：企業および組織の一覧